https://assets.capyfin.com/instruments/678fdc13234e27009c5d6080.png avatar
Beauty Health
🇺🇸 NASDAQ:SKIN
View Company
OverviewEarningsDividends
•
Jun 30, 2023

Beauty Health Q2 2023 Earnings Report

BeautyHealth reported double-digit net sales growth driven by demand for Hydrafacial and reaffirmed its 2023 net sales and 2025 financial guidance, while refining 2023 adjusted EBITDA margin guidance.

Key Takeaways

BeautyHealth reported a 13% year-over-year increase in net sales, reaching $117.5 million. Net income was $3.4 million, and the adjusted EBITDA margin was 15.1%. The company reaffirmed its 2023 net sales and long-term 2025 financial guidance, and refined its 2023 adjusted EBITDA margin to a more precise 18%-19% range.

Net sales increased by 13% year-over-year to $117.5 million.

Consumables net sales grew by 34% year-over-year.

Net income was $3.4 million.

Adjusted EBITDA margin was 15.1%.

Total Revenue
$118M
Previous year: $104M
+13.5%
EPS
$0.03
Previous year: $0.014
+114.3%
Gross Margin
57.8%
Previous year: 69.2%
-16.5%
Adjusted EBITDA
$17.8M
Previous year: $12.6M
+40.8%
Adjusted EBITDA Margin
15.1%
Previous year: 12.2%
+23.8%
Gross Profit
$67.9M
Previous year: $71.7M
-5.2%
Cash and Equivalents
$550M
Previous year: $821M
-33.0%
Free Cash Flow
$20.7M
Previous year: -$33.8M
-161.2%
Total Assets
$1.01B
Previous year: $1.21B
-17.1%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

The Company re-affirmed its fiscal year 2023 net sales due to continued demand for Hydrafacial, strong trends in China and ability to drive operating leverage, and refined its fiscal year 2023 adjusted EBITDA guidance to a range of 18-19% from 18-20% previously. The Company retracted its 2023 fiscal year 2023 adjusted gross margin guidance due to Q2 margin headwinds carrying into the back half of 2023. The Company re-affirmed its fiscal year 2025 long-range outlook, due to continued strong business fundamentals, fortified leadership team and its expected pipeline of innovation.

Positive Outlook

  • Continued demand for Hydrafacial.
  • Strong trends in China.
  • Ability to drive operating leverage.
  • Continued strong business fundamentals.
  • Fortified leadership team and its expected pipeline of innovation.

Challenges Ahead

  • No material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control.
  • Excludes any unannounced acquisitions, dispositions or financings during 2023.
  • Assumes a largely re-opened global market, which would be negatively impacted if closures related to COVID-19 or other restrictive measures are reimplemented.
  • Assumes no material deterioration in foreign currency exchange rates.
  • Q2 margin headwinds carrying into the back half of 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Beauty Health